Allogene retains control of cancer therapy after arbitration ruling

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. SWKS
7. ANET
8. CVS
9. SPY
10. XYZ

Go back to Allogene retains control of cancer therapy after arbitration ruling

Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis

December 15, 2025 5:39 PM EST

Arbitration Ruling Reaffirms Allogenes Full Control of Cemacabtagene Ansegedleucel (Cema-Cel)Decision Reconfirms Allogenes Expanded Sub-License Covering EU and UK Rights with Options for Japan and China, Clearing the Path for Allogene to Acquire Full Global Rights 1H 2026 Interim Futility Analysis from the Pivotal Phase 2 ALPHA3 Trial with Cema-Cel in First-Line (1L) Consolidation Large B-Cell Lymphoma (LBCL) Remains on Track

SOUTH SAN FRANCISCO, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company... More